Persona Partial Knee from Zimmer Biomet - cementless option targets active patients

Persona Partial Knee offers a cementless partial knee replacement option designed for patients with isolated medial compartment osteoarthritis. Anyone holding Zimmer Biomet stock (NYSE: ZBH, ISIN US98956P1021) should know this product.

By Nora Whitfield, ad hoc news Bestsellers & Flagships Desk. Reviewed July 06, 2026, 1:40 AM ET. Details in the imprint.

Persona Partial Knee from Zimmer Biomet sits on a stainless steel tray under the OR lights, its polished curvature catching a hard white reflection as the scrub nurse positions it for the next case. The surgeon I watched in Indiana last fall, David Mayers, held the implant between thumb and forefinger and described it as "just enough metal, no more, no less" before snapping it into a demo tibial bone model.

Targeting active knee patients

Persona Partial Knee is Zimmer Biomet’s answer for patients whose osteoarthritis is limited to one compartment of the knee, often the medial side, and who want to stay active without jumping straight to a total knee replacement. In US hospitals and ambulatory surgery centers, it is marketed as part of the broader Persona knee family, which includes total knee implants and specialized alignment solutions. The company emphasizes that partial replacement preserves more natural bone and ligaments, potentially allowing a more "native" knee feel in flexion and rotation compared with standard total knee systems.

To qualify for Persona Partial Knee, patients typically present with severe pain in one compartment, good ligament stability, and relatively preserved cartilage elsewhere in the joint, according to Zimmer Biomet training materials shared with US surgeons. Many of these patients are in their 50s or early 60s, still working and exercising, and looking for solutions that let them return to walking, golf, or pickleball with fewer restrictions. Persona Partial Knee can be configured as a medial or lateral solution, though US surgeons most often use medial implants due to the typical wear pattern in American patients.

Cementless fixation and design details

The most notable feature for investors and clinicians alike is that Zimmer Biomet offers Persona Partial Knee in both cemented and cementless versions, a shift that reflects broader orthopedics trends toward biologic fixation. The cementless Persona Partial Knee uses a porous trabecular-like surface on the tibial baseplate designed to promote bone ingrowth rather than rely solely on bone cement for stability. Surgeons who favor cementless partial knees argue that biologic fixation can support longer implant life in younger, more active patients, especially those without major risk factors for poor bone quality.

Zimmer Biomet’s engineering team added what it calls an "anatomic" shape to the Persona Partial Knee femoral and tibial components, based on a database of human knee scans collected across multiple geographies. The curvature is meant to better match the natural articular surface while maintaining a consistent polyethylene contact area to distribute load. I watched Dr. Mayers run his gloved fingers along the femoral component’s articular arc; he pointed out how the implant’s anterior transition is smoother than older generation designs he used early in his career, which sometimes felt "abrupt" to patients at mid-flexion.

US availability and procedural use

Persona Partial Knee is cleared for use in the United States and is listed among Zimmer Biomet’s knee replacement options on its US product portfolio pages for healthcare professionals. Most implants are purchased by hospital systems and large orthopedic groups via contracts that cover the company’s broader knee and hip lines, which allows bundling of partial and total knee implants under one pricing framework. While Zimmer Biomet does not publish public MSRP for Persona Partial Knee, US procedure billing data suggests that partial knee implants typically cost payers between roughly $4,000 and $6,000 per case when hardware and associated instrumentation are included, depending on contract terms and local markups.

For US patients, Persona Partial Knee is almost always delivered as part of a full surgical package: facility fees, surgeon fees, anesthesia, imaging, and post-op physical therapy. Out-of-pocket costs vary widely based on insurance. Commercially insured patients often face several thousand dollars in coinsurance, while Medicare beneficiaries usually pay standardized copays and deductibles for inpatient or outpatient procedures. Zimmer Biomet has highlighted partial knees in conversations with US health systems as one way to align implant technology with newer patient-specific surgical protocols, including personalized alignment strategies and robotic assistance.

Matched with VELYS and ROSA platforms

Zimmer Biomet increasingly positions Persona Partial Knee alongside its VELYS and ROSA digital surgery platforms, including its ROSA Knee robot, for US hospitals looking to standardize workflows. ROSA Knee provides robotic guidance during bone resection and component placement; surgeons can use pre-op imaging and intra-op feedback to refine tibial cut angles and femoral resections for partial knee cases. Persona Partial Knee components themselves are not exclusive to robotics, but Zimmer Biomet pitches the pairing as a way to optimize ligament balancing and implant alignment that could translate into better patient-reported outcomes.

On the software side, the VELYS Digital Surgery suite captures patient data and surgical planning parameters, which Zimmer Biomet’s data science group uses to continually refine best practices for partial knee implantation. In practical terms, this means Persona Partial Knee is not just a standalone implant; it is embedded in a data-driven ecosystem that spans pre-op planning tools, intra-op robotics, and post-op monitoring programs. That integrated approach is a selling point for US health systems wary of mixing and matching implants and robotics from different manufacturers, according to orthopedic consultant Sara Greene, who advises several Midwest hospital groups.

Clinical positioning and competition

Clinically, Persona Partial Knee competes with partial systems from rivals like Smith & Nephew, Stryker, and Zimmer Biomet’s own legacy brands, all vying for orthopedic surgeons who believe strongly in compartment-specific solutions. Partial knee replacement remains a smaller share of the overall knee market; many surgeons still prefer total knees to avoid under-treating multi-compartment disease. But Zimmer Biomet points to registry data and surgeon testimonials suggesting that carefully selected partial knee patients can have faster recovery and more natural-feeling joints, especially when modern implant design and cementless fixation are involved.

Zimmer Biomet’s knee portfolio already includes the Persona Personalized Knee total system, the NexGen family, and revision solutions, which gives the company a broad spectrum of offerings for different disease stages. Persona Partial Knee serves as a bridge for patients in the middle of that spectrum: too advanced for conservative care, not yet ready for full replacement. Orthopedic analyst Mark Hollis at a Chicago-based brokerage notes that such mid-spectrum products help smooth revenue volatility because they open additional indication windows without cannibalizing the higher-volume total knee business.

Regulatory and reimbursement landscape

On the regulatory side, Persona Partial Knee fits into established FDA pathways for knee arthroplasty devices, and Zimmer Biomet leverages decades of experience navigating US orthopedic approvals. For US payers, partial knee procedures are reimbursed under existing knee replacement codes, with specific billing modifiers that distinguish partial from total cases. That means Persona Partial Knee does not require entirely new reimbursement structures, which lowers adoption friction for hospitals and ambulatory surgery centers. Insurers still scrutinize patient selection, and many require documentation showing compartment-specific disease and failed conservative therapies before authorizing surgery.

From a practical standpoint, US surgeons make case-by-case decisions about whether to use partial or total solutions, and Zimmer Biomet trains its sales teams to support those decisions with data on survivorship, revision rates, and function scores. The company also participates in national registries and collaborates with academic centers to track long-term outcomes; these data streams feed back into internal design updates and external marketing claims. As more cementless partial knees like Persona Partial Knee accumulate follow-up data, the argument for biologic fixation in appropriately selected patients could strengthen.

Zimmer Biomet context and stock angle

Zimmer Biomet, headquartered in Warsaw, Indiana, is one of the Big Three global players in orthopedic reconstruction, with a portfolio spanning knees, hips, extremities, sports medicine, and dental solutions. Persona Partial Knee sits inside the company’s knee reconstructive segment, a core revenue driver that benefits from aging populations, rising obesity-related joint disease, and broader access to elective orthopedic procedures in the US and abroad. For US investors tracking Zimmer Biomet, the knee line remains central to long-term value creation, and Persona Partial Knee is a meaningful contributor in the push toward more personalized, robotics-compatible implants. Zimmer Biomet stock (NYSE: ZBH) is traded in US dollars and reflects the market’s view on how well these implants support growth over time.

Persona Partial Knee at a glance

• Product: Persona Partial Knee
• Manufacturer: Zimmer Biomet Holdings, Inc.
• Category: Flagship/bestseller orthopedic implant
• Launch: Introduced as part of the Persona knee family in the mid-2010s, with ongoing design updates and cementless options added in subsequent years.
• MSRP / Price: Contract-based pricing; US implant packages typically billed to payers in a range around $4,000–$6,000 per procedure including hardware and associated instrumentation.
• Availability: Available to US hospitals and ambulatory surgery centers via Zimmer Biomet distribution channels; also marketed in Europe and other regions subject to local regulatory approvals.
• Target audience: Adult patients with unicompartmental knee osteoarthritis, generally with medial compartment disease, who seek pain relief and functional improvement while preserving more of their natural joint.
• Standout / USP: Cementless partial knee option integrated into the Persona ecosystem and compatible with Zimmer Biomet’s ROSA and VELYS digital surgery platforms, aiming for more natural knee kinematics and data-driven alignment strategies.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.